Research graph
References from When does change become progression? Defining meaningful quantitative computed tomography thresholds in idiopathic pulmonary fibrosis. Local targets link to admitted publications; unresolved targets remain external evidence.
Idiopathic pulmonary fibrosis: state of the art for 2023
10.1183/13993003.00957-2022 · 2023 · External reference
Idiopathic pulmonary fibrosis (an update) and progressive pulmonary fibrosis in adults: an official ATS/ERS/JRS/ALAT clinical practice guideline
10.1164/rccm.202202-0399st · 2022 · External reference
Idiopathic pulmonary fibrosis: physiologic tests, quantitative CT indexes, and CT visual scores as predictors of mortality
10.1148/radiol.2463062200 · 2008 · External reference
Towards the adoption of quantitative computed tomography in the management of interstitial lung disease
10.1183/16000617.0055-2023 · 2024 · External reference
Machine learning in radiology: the new frontier in interstitial lung diseases
10.1016/s2589-7500(22)00230-8 · 2023 · External reference
Quantification of interstitial lung diseases, from the AJR special series on quantitative imaging
10.2214/ajr.24.32053 · 2025 · External reference
10.1093/ajrccm/aamag245 · Admitted local publication
Minimal clinically important difference: defining what really matters to patients
10.1001/jama.2014.13128 · 2014 · External reference
Minimal clinically important difference in idiopathic pulmonary fibrosis
10.1183/20734735.0345-2020 · 2021 · External reference
Quantitative high-resolution computed tomography fibrosis score: performance characteristics in idiopathic pulmonary fibrosis
10.1183/13993003.01384-2018 · 2018 · External reference
Minimum clinically important difference in quantitative lung fibrosis score associated with all-cause mortality in idiopathic pulmonary fibrosis: subanalysis from two phase II trials of pamrevlumab
10.1136/bmjopen-2024-094559 · 2025 · External reference
Meaningful endpoints for idiopathic pulmonary fibrosis (IPF) clinical trials: emphasis on “feels, functions, survives.” Report of a collaborative discussion in a symposium with direct engagement from representatives of patients, investigators, the National Institutes of Health, a patient advocacy organization, and a regulatory agency
10.1164/rccm.202312-2213so · 2024 · External reference
Sources of variation in quantitative computed tomography of the lung
10.1097/rti.0b013e31829efbe9 · 2013 · External reference
Quantitative CT analysis of diffuse lung disease
10.1148/rg.2020190099 · 2020 · External reference
